Revolution Medicines' initiation of early access shipments for daraxonrasib following striking Phase 3 results represents tangible progress against pancreatic ductal adenocarcinoma, a disease with five-year survival below 13% and limited therapeutic options. The STAT report captures the immediate rollout under FDA authorization but overlooks critical context from prior KRAS-targeted research, including the CodeBreaK 100 trial (observational extension of an RCT, n=126 for G12C cohort) published in NEJM 2022, which showed modest response rates and highlighted resistance patterns now informing daraxonrasib's dual inhibition approach. A 2024 Lancet Oncology systematic review of 18 pancreatic trials (mostly Phase 2/3 RCTs, total n>4,000) underscores that median survival gains rarely exceed 3-4 months with standard chemotherapy, making the reported near-doubling of survival a potential outlier warranting scrutiny for selection bias and conflicts of interest in industry-sponsored studies. The coverage also misses how this accelerated access aligns with post-2023 FDA guidance shifts favoring real-world evidence, yet raises equity concerns as early programs disproportionately benefit insured U.S. patients, echoing patterns in prior oncology expansions like those for KRAS inhibitors in lung cancer. Peer-reviewed follow-up data remain absent, with the Phase 3 trial details unpublished beyond company announcements, limiting assessment of sample size, endpoints, and adverse events.